ライフサイエンスコーパス: patency

1 eling of follicular epithelium (also called 'patency').

2 RA was found to be patent in 24 cases (84.8% patency).

3 oups (67.4% versus 65.7%, P=0.92 for primary patency).

4 recurrent restenosis (100% rate of Secondary patency).

5 rements and implications for long-term graft patency.

6 conduit function and possibly improve graft patency.

7 he primary end point was 3-year angiographic patency.

8 significantly influenced long-term RA graft patency.

9 rinolysis to physiologically maintain vessel patency.

10 motoneurons important for maintaining airway patency.

11 nd/MRI were used subsequently to document PV patency.

12 e muscles of respiration and maintain airway patency.

13 c evidence of ostium patency and canalicular patency.

14 lesion revascularization and loss of primary patency.

15 activation of canonical Wnt causes PF-suture patency.

16 offers a promising target for modulating DA patency.

17 nical challenge in determining tibial artery patency.

18 r to LITA patency and is much better than SV patency.

19 ebs, may also have adverse effects on airway patency.

20 ent prognostic factors associated with stent patency.

21 xhibited a delay in the onset of blood-stage patency.

22 nt benefit of statin treatment on vein graft patency.

23 amages peri-infarct tissue, despite arterial patency.

24 y invasive method for reestablishing luminal patency.

25 s vein graft disease, and improve vein graft patency.

26 vein graft did not result in greater 1-year patency.

27 ntity; increased Eph-B activity improves AVF patency.

28 clot stability and maintaining blood vessel patency.

29 recoil, when it did occur, did not influence patency.

30 e showing obstruction and the second showing patency.

31 ic recoil and determine its effect on access patency.

32 associations are explained by reduced airway patency.

33 isted patency, and 89% (74-93) had secondary patency.

34 a improved medium-term arteriovenous fistula patency.

35 d a preservation of the entire vascular tree patency.

36 al and uterine morphology and fallopian tube patency.

37 At 12 months, 28% (17-40) had primary patency, 38% (26-51) had primary assisted patency, and 8

38 rafts) patency was 82% and SV (n=364 grafts) patency, 47% (P<0.0001).

39 Outcomes at 1 year were primary patency, 63.1% (95% CI, 57.3-68.6); repeat revasculariza

40 , 63% (95% CI 47-72) of patients had primary patency, 73% (57-81) had primary assisted patency, and 9

41 ival (86.6% vs. 77.9%, p = 0.02) and primary patency (74.8% vs. 26.5%, p < 0.01).

42 (22.4% vs. 41.9%, p = 0.019), greater vessel patency (75.0% vs. 57.1%, p =0.025), and similar death,

43 TA per the Kaplan-Meier estimate for primary patency (89.0% versus 65.0% at 365 days; log-rank P<0.00

44 on to Inhibit Restenosis and Maintain Vessel Patency-A Pilot Study of Anti-Restenosis Treatment) was

45 Status of graft patency across time was analyzed by longitudinal nonline

46 Secondary end points included anatomic patency, adverse event rate, and return to operating roo

47 able antithrombotic agents to restore vessel patency after arterial occlusion.

48 Stenting has been shown to improve patency after femoral artery revascularization compared

49 f GpIbalpha-VWF interactions restores vessel patency after occlusive thrombosis by specifically disag

50 aphic (US) nephrostograms to assess ureteral patency after percutaneous nephrolithotomy (PCNL) in thi

51 occurrence does not influence access primary patency after PTA.

52 r PTX, Cook, IN) has shown to improve vessel patency after superficial femoral angioplasty.

53 us methods that can be used to measure nasal patency, airflow and resistance, mainly peak nasal inspi

54 Restoration of vessel patency alone failed to reverse tubulointerstitial damag

55 in the poststenotic kidney, restoring vessel patency alone is insufficient to recover kidney function

56 ine associated with primary unassisted graft patency among participants in a randomized trial that co

57 llow-up, the incidence of primary unassisted patency among participants using aspirin at baseline was

58 use was also associated with improved lesion patency among patients undergoing infrapopliteal angiopl

59 At 12 months, the rate of primary patency among patients who had undergone angioplasty wit

60 mation exists on the intermediate-term graft patency and 5-year clinical outcomes of patients receivi

61 implantation is associated with longer stent patency and a lower risk of reintervention.

62 he Kolliker-Fuse (KF) maintains upper airway patency and a normal respiratory pattern.

63 may be useful for predicting long-term graft patency and assessing grafts intraoperatively in patient

64 12 months and endoscopic evidence of ostium patency and canalicular patency.

65 conducted to assess whether DES also improve patency and clinical outcome of infrapopliteal lesions.

66 propriate conduit to improve long-term graft patency and clinical outcomes of patients undergoing CAB

67 thrombi resulting in fast restoration of MCA patency and consequently reduced cerebral infarct sizes

68 lial cells plays a vital role in maintaining patency and homeostasis.

69 ing GpIbalpha-VWF inhibitors restored vessel patency and improved outcome in a mouse model of ischemi

70 c arteries (BITA) have demonstrated superior patency and improved survival in patients undergoing cor

71 data may be helpful in predicting long-term patency and in the decision of whether to revise a quest

72 e SXT-THV, as demonstrated by improved valve patency and increased transfemoral access safety.

73 Two radiologists evaluated portal vein patency and intrahepatic portal branches, the morphologi

74 Rates of 1-year FitzGibbon grade A patency and intraoperative revision were compared based

75 RA patency is similar to LITA patency and is much better than SV patency.

76 vened segments, both of which may jeopardize patency and lead to recurrent symptoms, functional impai

77 erform and are capable of demonstrating both patency and obstruction of the ureter.

78 oms partially improved with a combination of patency and reflux on syringing.

79 iker-Fuse nucleus (KF) controls upper airway patency and regulates respiration, in particular the ins

80 high capillary density, diminished vascular patency and severe cardiac dysfunction.

81 n angioplasty strategy has equivalent 1-year patency and should be preferred over primary stenting.

82 of the greater achievement of infarct artery patency and speed of reperfusion.

83 ss (FS), early and late complications, stent patency and survival.

84 tial size was not predictive of final ostial patency and symptomatic resolution of epiphora.

85 TTP was inversely correlated with vascular patency and verteporfin uptake, suggesting interstitial

86 ts were evaluated with objective (anatomical patency) and subjective (symptomatic cure) success rates

87 ry patency, 38% (26-51) had primary assisted patency, and 89% (74-93) had secondary patency.

88 ry patency, 73% (57-81) had primary assisted patency, and 97% (85-98) had secondary patency, with mos

89 , with late luminal enlargement, side-branch patency, and development of a signal-rich, low-attenuati

90 and door-to-balloon times, pre-PPCI coronary patency, and infarct-related artery location.

91 Cs displayed good attachment, stabilization, patency, and typical vascular structure when seeded on d

92 of aggressive statin treatment on vein graft patency are required, in order to safely translate this

93 Late survival and target vessel patency are satisfactory.

94 and as good an indication of objective nasal patency as formal rhinomanometry and has the advantage t

95 or maturation of schistosomes in the host to patency, as we reproducibly recovered significantly fewe

96 mary efficacy assessment was change in nasal patency assessed by measuring the minimal cross-sectiona

97 by primary, primary assisted, and secondary patencies at 6 months.

98 ndary end points included angiographic graft patency at 1 week after CABG, myocardial infarction, str

99 was no significant difference in study graft patency at 1 year after CABG (radial artery, 238/266; 89

100 The primary end point was angiographic graft patency at 1 year after CABG.

101 reated with the helical stent who maintained patency at 12 and 24 months was 80% and 72%, respectivel

102 Primary patency at 12 months (360 +/- 30 days) was achieved in 7

103 coated balloon resulted in a rate of primary patency at 12 months that was higher than the rate with

104 primary effectiveness end point was primary patency at 12 months.

105 dimensions and function, and aortic size and patency at 14.1 +/- 1.2 months and 33.6 +/- 9.6 months i

106 Primary patency at 3 months was higher in the BPB group than the

107 e primary endpoint was arteriovenous fistula patency at 3 months.

108 te (primary, primary assisted, and secondary patency at 6 and 12 months), (2) improvement of quality

109 nhibitor treatment effectively improved TEVG patency at 6 mo compared to the untreated control group

110 Sustained device patency at 6 months was confirmed by left-to-right shunt

111 The secondary end point was anatomic patency based on nasolacrimal syringing and categorized

112 secondary patency, with most loss of primary patency because of thrombosis.

113 esions demonstrated significant clinical and patency benefits for heparin-bonded covered stents compa

114 id not show significant differences in graft patency between groups.

115 is known about the differences in long-term patency between radial free and T grafts.

116 revealed no significant difference in graft patency between the 2 BITA configurations.

117 x; (b) >50% patent but some reflux; (c) some patency but >50% reflux; or (d) nonpatent, 100% reflux.

118 e prevalence of tibial artery and pedal arch patency by angiography in these patients.

119 Primary patency by Kaplan-Meier analysis at 12 months (360 days)

120 to the artery, potentially improving vessel patency by reducing restenosis.

121 it only showed a trend for increasing nasal patency by using objective measures.

122 study was to determine whether upper airway patency can be improved using chemogenetic approach by d

123 DES group exhibited superior 2-year primary patency compared with the provisional BMS group (83.4% v

124 Functional tests examining ET patency confirmed a reduced clearing ability in the hete

125 In contrast, saphenous vein graft patency declined over time and similarly in patients wit

126 The primary efficacy end point was primary patency, defined as freedom from restenosis or clinicall

127 e primary study end point was 1-year primary patency, defined as freedom from target-lesion restenosi

128 and cell seeding to investigate the vascular patency, degree of decellularization, and scaffold bioco

129 plete recovery, aesthetic, functional (nasal patency, eye closure, speech and swallowing) and psychol

130 ) and were less likely to be lost because of patency failure (0 vs. 4; log rank, p = .04).

131 des protection comparable to heparin against patency failure.

132 reconstructed rat aorta confirmed equivalent patency, flow and burst strength, and histological analy

133 false lumen thrombosis (FLT) and false lumen patency (FLP) was determined and the effect on post-TEVA

134 resulted in significantly lower FitzGibbon A patency for arterial and saphenous vein graft conduits a

135 deled probabilities of primary and secondary patency for each access type, with success modified by a

136 tents and drug-coated balloons have improved patency for moderate-length lesions, whereas others allo

137 The 24-month assessments included primary patency, freedom from clinically driven target lesion re

138 iaphragmatic contraction that preserves lung patency has yet to be explored.

139 ested EVH is associated with decreased graft patency, higher rates of cardiovascular complications (e

140 e relationship between survival and vascular patency immediately after TIPS.

141 and CC angiographic imaging regarding graft patency in 114 of 115 grafts identified with CC angiogra

142 olysis In Myocardial Infarction flow grade 3 patency in 15% of patients with acute myocardial infarct

143 ate platelet-rich thrombi and restore vessel patency in acute thrombotic disorders such as ischemic s

144 Maintaining good blood patency in catheterized rats is not difficult.

145 Conclusion: Maintaining good blood patency in catheterized rats is not difficult.

146 Contrast-enhanced US demonstrated ureteral patency in eight studies and obstruction in two.

147 the importance of including vascular access patency in future studies of BP management in hemodialys

148 CS CABG Patency Study showed excellent graft patency in patients assessed by 64-slice computed tomogr

149 bypass grafting because they have excellent patency in patients with and without diabetes even after

150 use in the assessment of allograft vascular patency in patients with graft dysfunction, either delay

151 creasingly used to maintain long-term venous patency in patients with iliofemoral venous outflow obst

152 membrane receptor mediating JH regulation of patency in the red flour beetle.

153 The median duration of stent patency in weeks (w) were as follows: 20 w in patients p

154 eHAT is initially asymptomatic and arterial patency is monitored with percutaneous Doppler ultrasoun

155 n for the purpose of maintaining canalicular patency is not necessary when performing endonasal DCR i

156 RA patency is similar to LITA patency and is much better th

157 artery stenosis, we hypothesized that graft patency is worse in patients with than without diabetes.

158 tion of liver burden and delayed blood-stage patency, leading to a disease outcome different from tha

159 sponse that influences vessel remodeling and patency, limiting long-term benefits of cardiovascular i

160 The Kaplan-Meier analysis for time to first patency loss was not significantly different (log rank =

161 versus PTA with significantly higher primary patency, lower CD-TLR, and similar functional status imp

162 Intuitively, sustained vessel patency may be considered as a main variable related to

163 ocardial infarction; superior infarct artery patency, no reocclusions, and 1% mortality resulted.

164 target-lesion revascularization and loss in patency, no significant differences prevailed between th

165 anch occlusion (ABO, n=17) and atrial branch patency (non-ABO, n=92).

166 ]; Asp/Pla) therapy achieved nearly half the patency observed in the SCID/bg mouse (NK Ab: 0.356 +/-

167 FitzGibbon grade A patency occurred significantly less often in grafts with

168 hs), primary patency was 94%, with secondary patency of 95.3%.

169 The cumulative patency of bilateral SEMS or PS stents was significantly

170 amine the influence of diabetes on long-term patency of bypass grafts.

171 about the influence of diabetes on long-term patency of bypass grafts.

172 thesis, diabetes did not influence long-term patency of bypass grafts.

173 ecular strategies that promote the long-term patency of cardiovascular interventions.

174 uct cancer patients and results in prolonged patency of hilar bile ducts, a trend for longer survival

175 s, diabetes was associated with higher early patency of ITA grafts (odds ratio: 0.63; 95% confidence

176 e limits: 0.43 to 0.91; p = 0.013), but late patency of ITA grafts was similar in patients with and w

177 (ERDP/ASA) prolongs primary unassisted graft patency of newly created hemodialysis arteriovenous graf

178 ith a trend toward longer primary unassisted patency of newly placed hemodialysis grafts similar to t

179 nificance of the R-Ras-Akt signaling for the patency of regenerating blood vessels.

180 Early and late patency of saphenous vein grafts were similar in patient

181 The patency of target vessels is important for survival.

182 oading based on the contractility state, the patency of the actin cytoskeleton, and the connections i

183 gas and oxygenation parameters and maintain patency of the fetal circulation.

184 E(2)) plays a major role both in maintaining patency of the fetal ductus arteriosus and in closure of

185 , when ARA290 was systemically administered, patency of the microvasculature was maintained.

186 day 3: postmortem examination confirmed the patency of the stent.

187 The primary efficacy end point was primary patency of the target lesion at 12 months (defined as fr

188 dysfunction, it is critical to determine the patency of the transplant vasculature to guide clinical

189 hy, and ulnar frame count to investigate the patency of the ulnopalmar arches, as well as handgrip st

190 ngue muscles and are critical in maintaining patency of the upper airway during respiration.

191 Imaging data on the patency of the vertebral arteries and posterior communic

192 Primary end point was 6-month primary binary patency of treated lesions, defined as </=50% stenosis o

193 A follow-up after 12 and 24 months showed patency of treated vessels in 84% and 76% of patients, r

194 Conclusion Persistent patency of vasculature within the coagulated zone from I

195 technical success and higher 1-year primary patency only if provisional stenting is considered targe

196 ociate with prolongation of cumulative graft patency or participant survival.

197 Morphologic parameters evaluated were IMA patency, origin of the IMA in relation to the aneurysm s

198 rformed to determine long-term radial artery patency over a 15-year period.

199 with sterile protection and delay in time to patency (P(corrected)=0.005).

200 RA patency was not different from LITA patency (P=0.3).

201 n important role in maintaining upper airway patency, particularly during sleep, and modulating upper

202 Primary patency per Kaplan-Meier estimates at day 365 was 82.3%

203 The high rate of MPV patency post-TIPS placement suggests flow reestablishmen

204 hronic obstructive pulmonary disease, airway patency problems, and prolonged mechanical ventilation.

205 hronic obstructive pulmonary disease; airway patency problems; or prolonged mechanical ventilation.

206 hways associated with neuromuscular junction patency (providing molecular evidence of sarcopenia-rela

207 Good patency rate (100%) with self-expandable metallic stents

208 imary aim of the trial is to compare (1) the patency rate (primary, primary assisted, and secondary p

209 Eighty-nine percent MPV patency rate and 82% survival were achieved at 5 years.

210 Primary endpoint, primary patency rate at 12 months, was obtained in 92.1% (35 pat

211 The 20-year patency rate of RA grafts is good, and not inferior to t

212 elf-expanding nitinol stent has improved the patency rate of SFA after percutaneous transluminal angi

213 ntry technique is associated with a very low patency rate regardless of the type of stent used.

214 eved without surgical repair, with a carotid patency rate superior to published data after surgical c

215 The 1-year primary patency rate was significantly higher in the group with

216 TA, P=0.025 for superiority) and the primary patency rate was significantly higher with DCB (76.3% fo

217 ter-Society Consensus class D), the 12-month patency rate was significantly longer in VIA patients in

218 On the basis of the high primary patency rate, absence of stent fracture, and significant

219 luting stents is associated with a very high patency rate.

220 drug-eluting stents (DES) have shown better patency rates and are standard practice nowadays.

221 opliteal lesions, DES provide better 6-month patency rates and less amputations after 6 and 12 months

222 her the "best of both worlds": the excellent patency rates and survival benefits associated with the

223 The primary patency rates at 6 and 12 months were 67% and 50%.

224 The secondary patency rates at 6 and 12 months were 75% and 67%.

225 believed to improve the graft longevity and patency rates at distal graft anastomoses.

226 rtery bypass graft surgery suffer from lower patency rates compared to left internal mammary artery.

227 , BPB significantly improved 3 month primary patency rates for arteriovenous fistulae.

228 The 12-month primary patency rates in the Viabahn and BMS groups were: intent

229 ith thrombosis-free patency (thrombosis-free patency rates of 54%, 38%, and 26% for low, middle, and

230 nterior descending artery alongside the good patency rates of drug-eluting stents, which outlive saph

231 Off-pump CABG resulted in lower FitzGibbon A patency rates than on-pump CABG for arterial conduits (8

232 nstrated that it provides superior long-term patency rates to the saphenous vein in most situations.

233 Six-month patency rates were 48.0% for DES and 35.1% for PTA+/-BMS

234 mulative 1-, 2-, 3-, 5-, and 10-year primary patency rates were 64%, 59%, 54%, 45%, and 45%, respecti

235 Clinical outcomes and patency rates were assessed at 1, 6, and 12 months.

236 me relevant secondary outcomes such as graft patency, rates of thrombosis, and interventions, other p

237 At 3 months and beyond, the patency ratio (lumen area/reference vessel area) of BMS

238 onal stent placement) and long-term (primary patency, repeat revascularization, major amputation, all

239 o open surgery, with good 12-month follow-up patency results comparable to surgery.

240 Recently, the MICS CABG Patency Study showed excellent graft patency in patients

241 In the RAPS (Radial Artery Patency Study) study, complete graft occlusion was less

242 (Multicentre Radial Artery Patency Study: 5 Year Results; NCT00187356).

243 Preprocedural patency tests have thus no added benefit to prevent isch

244 er, more convenient way to evaluate ureteral patency than fluoroscopy.

245 ent prolongation of primary unassisted graft patency that approached statistical significance (adjust

246 Going along with the improved patency, the cell-seeded TEV demonstrated less neointima

247 s were fractional flow reserve during vessel patency, the quantitative intracoronary ECG ST-segment e

248 a negative association with thrombosis-free patency (thrombosis-free patency rates of 54%, 38%, and

249 primary effectiveness end point was primary patency through 12 months.

250 ef at final follow-up, and primary/secondary patency through 5 years.

251 Blood contacting surfaces maintain their patency through physico-chemical properties of a functio

252 ee vaccinees (3/14, 21%), and delays time to patency through substantial reduction of liver-stage par

253 The EVFW is an intraoperative gauge of patency through the trabecular outflow pathway.

254 oMimics 3D helical stent, there was improved patency to 2 years.

255 n activator (t-PA) is recommended to restore patency to occluded catheters.

256 ant distal biliary obstruction with superior patency to plastic stents.

257 grafts had similar and acceptable long-term patency to support their use as a coronary artery bypass

258 DCB resulted in higher primary patency versus PTA (82.2% versus 52.4%; P<0.001).

259 of halofuginone dramatically increased lumen patency via adaptive remodeling and selective inhibition

260 emale sexual maturation, measured by vaginal patency (VP).

261 - 1.8 months, the success rate of anatomical patency was 100% (27/27) and the success rate of symptom

262 At 3-month follow-up, primary venous patency was 100% in the ultrasound-assisted catheter-dir

263 In Group 2, the median duration of PS patency was 17 w and 18 w for unilateral and bilateral p

264 ly (p = 0.0004); the median duration of SEMS patency was 24 w and 29 w for unilateral and bilateral p

265 Six-month primary patency was 34.8% in grafts and 47.1% in fistulas.

266 right internal thoracic artery (n=15 grafts) patency was 80% (P=0.6).

267 Overall RA (n=420 grafts) patency was 82% and SV (n=364 grafts) patency, 47% (P<0.

268 Duplex ultrasound patency was 84.6% for DA+DCB, 81.3% for DCB (P=0.78), an

269 (n=287 grafts including 9 sequential grafts) patency was 85% and right internal thoracic artery (n=15

270 of 17.1 months (range: 1-70 months), primary patency was 94%, with secondary patency of 95.3%.

271 Patency was a secondary end point.

272 e accuracy of CT for the assessment of graft patency was also analyzed.

273 FitzGibbon grade A patency was also inversely correlated with increasing PI

274 Preservation of vascular patency was assessed by imaging, cell and antigen remova

275 tive anticoagulation was standard and venous patency was assessed by routine computed tomographic sca

276 iation of variables with the risk of loss of patency was assessed by using a Cox proportional hazards

277 Subclavian vein patency was assessed in 26 patients.

278 Nevertheless, secondary patency was close to 100%, and long-term survival was go

279 SVG patency was determined 6 months after surgery by compute

280 red TTF and/or PI in 2738 grafts, and 1-year patency was determined in 1710 (62.5%) of these grafts.

281 Access patency was estimated by using Kaplan-Meier survival met

282 The patency was evaluated by Kaplan-Meier analysis.

283 US and fluoroscopic assessments of ureteral patency was evaluated by using a Clopper-Pearson exact b

284 Venous internal lumen patency was maintained for the duration of implantation.

285 RA patency was not different from LITA patency (P=0.3).

286 was 5.8 months, and median duration of port patency was not reached.

287 Assessment for patency was performed every 8 hrs in lumens without cont

288 d after 48 (11%) regular pDUS where arterial patency was questioned: 32 extra pDUS, 14 computed tomog

289 As a result of these deficits, vessel patency was reduced by 25%, and vessel leakiness was inc

290 Immediate and long-term postoperative vein patency was similar to patients without hypercoagulabili

291 ITA graft patency was stable over time and similar in patients wit

292 durations of the primary and secondary stent patency were 114.7+/-15.1 and 146.4+/-21.2 days, respect

293 At 1 year, primary and secondary patency were 96% and 99% for nonthrombotic, 87% and 89%

294 cation rates and a superior cumulative stent patency when compared with PS placement in all Bismuth c

295 with DCB showed significantly higher primary patency when compared with PTA (78.9% vs. 50.1%; p < 0.0

296 iod, during which we analyzed hepatic artery patency with Doppler ultrasound at 1, 3, 6, and 12 month

297 ng with Ephrin-B2/Fc showed improved fistula patency with less wall thickness.

298 isted patency, and 97% (85-98) had secondary patency, with most loss of primary patency because of th

299 the proportion of grafts with loss of native patency within 12 months.

300 ompared with portal veins, and only arterial patency within an ablation zone was related to local tum